{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:29:50Z","timestamp":1787027390406,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum M\u00fcnster"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The efficient and safe transfection of hematopoietic cells is a major hurdle that limits efficacy of therapeutic approaches like RNA-interference. We therefore used our modular\n                    <jats:italic>EL<\/jats:italic>\n                    ectrostatic\n                    <jats:italic>A<\/jats:italic>\n                    ntibody si\n                    <jats:italic>R<\/jats:italic>\n                    NA\n                    <jats:italic>T<\/jats:italic>\n                    argeted therapy platform (ELART) to develop nanocarriers decorated with antibodies for delivery of siRNA into hematopoietic CD20-, CD22-, or CD33-positive cells. To analyze internalization efficacy into tumor cells, we applied nanocarriers loaded with Cy3- or Cy5-labeled siRNA and reached nearly all target cells within 1\u20134\u00a0h. Exposure to Cy5-labeled non-functional siRNAs resulted in reduction of the mitochondrial membrane potential and reduced viability, as detected in tetramethylrhodamine methyl ester (TMRM) and CellTiter-Glo (CTG) assays. We concluded that with our modular nanocarrier system, we can transport cytotoxic agents such as cyanine dyes when bound to siRNA, as ELART nanocarriers safely complex anionic siRNA electrostatically and releases it intracellularly within the target cell. This proof-of-concept study shows that ELART nanocarriers can transport anti-cancer agents utilizing siRNA as carrier substance.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-66482-5","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:47:06Z","timestamp":1787024826000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Transport of cytotoxic cyanine dyes coupled to siRNA into hematopoietic cancer cells with CD20-, CD22- or CD33-targeting ELART nanocarriers"],"prefix":"10.1038","volume":"16","author":[{"given":"Timo","family":"Krassuski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"B\u00e4umer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Niland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Grunert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Wittmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes A.","family":"Eble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang E.","family":"Berdel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"B\u00e4umer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"66482_CR1","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1186\/s12951-023-02147-z","volume":"21","author":"SS Ali Zaidi","year":"2023","unstructured":"Ali Zaidi, S. S. et al. Engineering siRNA therapeutics: challenges and strategies. J. Nanobiotechnol. 21, 381. https:\/\/doi.org\/10.1186\/s12951-023-02147-z (2023).","journal-title":"J. Nanobiotechnol."},{"key":"66482_CR2","doi-asserted-by":"publisher","first-page":"1637958","DOI":"10.3389\/fphar.2025.1637958","volume":"16","author":"CE Wang","year":"2025","unstructured":"Wang, C. E., Zhen, D., Yang, L. & Li, G. Clinical development prospects of siRNA drugs for tumor therapy: analysis of clinical trial registration data from 2004 to 2024. Front. Pharmacol. 16, 1637958. https:\/\/doi.org\/10.3389\/fphar.2025.1637958 (2025).","journal-title":"Front. Pharmacol."},{"key":"66482_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3390\/nano7040077","volume":"7","author":"K Tatiparti","year":"2017","unstructured":"Tatiparti, K., Sau, S., Kashaw, S. K. & Iyer, A. K. siRNA delivery strategies: A comprehensive review of recent developments. Nanomaterials (Basel Switzerland). 7, 77. https:\/\/doi.org\/10.3390\/nano7040077 (2017).","journal-title":"Nanomaterials (Basel Switzerland)"},{"key":"66482_CR4","doi-asserted-by":"publisher","first-page":"17184","DOI":"10.1038\/srep17184","volume":"5","author":"Y Diener","year":"2015","unstructured":"Diener, Y. et al. RNA-based, transient modulation of gene expression in human haematopoietic stem and progenitor cells. Sci. Rep. 5, 17184. https:\/\/doi.org\/10.1038\/srep17184 (2015).","journal-title":"Sci. Rep."},{"key":"66482_CR5","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s13045-022-01390-5","volume":"15","author":"N B\u00e4umer","year":"2022","unstructured":"B\u00e4umer, N. et al. Electrostatic anti-CD33-antibody-protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia. J. Hematol. Oncol. 15, 171. https:\/\/doi.org\/10.1186\/s13045-022-01390-5 (2022).","journal-title":"J. Hematol. Oncol."},{"issue":"15","key":"66482_CR6","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1038\/s41388-022-02241-w","volume":"41","author":"N B\u00e4umer","year":"2022","unstructured":"B\u00e4umer, N. et al. Targeted siRNA nanocarrier: A platform technology for cancer treatment. Oncogene Apr. 41 (15), 2210\u20132224. https:\/\/doi.org\/10.1038\/s41388-022-02241-w (2022).","journal-title":"Oncogene Apr"},{"key":"66482_CR7","doi-asserted-by":"publisher","first-page":"e202109769","DOI":"10.1002\/anie.202109769","volume":"61","author":"A Faust","year":"2022","unstructured":"Faust, A. et al. Tumor-Cell-Specific Targeting of Ibrutinib: Introducing Electrostatic Antibody-Inhibitor Conjugates (AiCs). Angew. Chem. Int. Ed. Engl. 61, e202109769. https:\/\/doi.org\/10.1002\/anie.202109769 (2022).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"issue":"44","key":"66482_CR8","doi-asserted-by":"publisher","first-page":"8079","DOI":"10.1039\/d4cc06569g","volume":"28","author":"A Faust","year":"2025","unstructured":"Faust, A. et al. Photodynamic ROS inducers delivered via electrostatic antibody targeted (ELART) nanocarriers incorporate into tumour cells and inhibit colony growth. Chem Commun. (Camb) May. 28 (44), 8079\u20138082. https:\/\/doi.org\/10.1039\/d4cc06569g (2025).","journal-title":"Chem Commun. (Camb) May"},{"key":"66482_CR9","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/gb-2007-8-9-227","volume":"8","author":"R Balhorn","year":"2007","unstructured":"Balhorn, R. The protamine family of sperm nuclear proteins. Genome Biol. 8, 227; https:\/\/doi.org\/10.1186\/gb-2007-8-9-227 (2007).","journal-title":"Genome Biol."},{"key":"66482_CR10","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1039\/D4BM00003J","volume":"12","author":"J Liu","year":"2024","unstructured":"Liu, J. et al. A mitochondria-targeting heptamethine cyanine-chlorambucil formulated polymeric nanoparticle to potentiate native tumor chemotherapeutic efficacy. Biomaterials Sci. 12, 2614\u20132625. https:\/\/doi.org\/10.1039\/D4BM00003J (2024).","journal-title":"Biomaterials Sci."},{"key":"66482_CR11","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1021\/acs.accounts.0c00733","volume":"54","author":"SM Usama","year":"2021","unstructured":"Usama, S. M. & Burgess, K. Hows and whys of tumor-seeking dyes. Acc. Chem. Res. 54, 2121\u20132131. https:\/\/doi.org\/10.1021\/acs.accounts.0c00733 (2021).","journal-title":"Acc. Chem. Res."},{"key":"66482_CR12","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.biomaterials.2013.10.033","volume":"35","author":"E Zhang","year":"2014","unstructured":"Zhang, E., Luo, S., Tan, X. & Shi, C. Mechanistic study of IR-780 dye as a potential tumor targeting and drug delivery agent. Biomaterials 35, 771\u2013778. https:\/\/doi.org\/10.1016\/j.biomaterials.2013.10.033 (2014).","journal-title":"Biomaterials"},{"key":"66482_CR13","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s42004-024-01256-6","volume":"7","author":"Z Kej\u00edk","year":"2024","unstructured":"Kej\u00edk, Z. et al. Cyanine dyes in the mitochondria-targeting photodynamic and photothermal therapy. Commun. Chem. 7, 180. https:\/\/doi.org\/10.1038\/s42004-024-01256-6 (2024).","journal-title":"Commun. Chem."},{"key":"66482_CR14","doi-asserted-by":"publisher","first-page":"1700262","DOI":"10.1002\/adhm.201700262","volume":"6","author":"P Bhattarai","year":"2017","unstructured":"Bhattarai, P. & Dai, Z. Cyanine based nanoprobes for cancer theranostics. Adv. Healthc. Mater. 6, 1700262. https:\/\/doi.org\/10.1002\/adhm.201700262 (2017).","journal-title":"Adv. Healthc. Mater."},{"key":"66482_CR15","doi-asserted-by":"publisher","first-page":"5581","DOI":"10.3390\/molecules29235581","volume":"29","author":"A Maia","year":"2024","unstructured":"Maia, A. et al. A new demand for improved selectivity and potency of cyanine dyes as antiproliferative agents against colorectal cancer cells. Molecules (Basel Switzerland). 29, 5581. https:\/\/doi.org\/10.3390\/molecules29235581 (2024).","journal-title":"Molecules (Basel Switzerland)"},{"key":"66482_CR16","doi-asserted-by":"publisher","first-page":"862","DOI":"10.3390\/ijms24010862","volume":"24","author":"G Jo","year":"2023","unstructured":"Jo, G., Kim, E. J. & Hyun, H. Enhanced tumor uptake and retention of cyanine dye-albumin complex for tumor-targeted imaging and phototherapy. Int. J. Mol. Sci. 24, 862. https:\/\/doi.org\/10.3390\/ijms24010862 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"66482_CR17","doi-asserted-by":"publisher","first-page":"4155","DOI":"10.3390\/cancers16244155","volume":"16","author":"Y Park","year":"2024","unstructured":"Park, Y., Yang, J. & Hyun, H. A. phthalimide-functionalized heptamethine cyanine dye for tumor-targeted photothermal therapy. Cancers 16, 4155. https:\/\/doi.org\/10.3390\/cancers16244155 (2024).","journal-title":"Cancers"},{"key":"66482_CR18","doi-asserted-by":"publisher","first-page":"8351","DOI":"10.1039\/c7sc03169f","volume":"8","author":"AP Thomas","year":"2017","unstructured":"Thomas, A. P., Palanikumar, L., Jeena, M. T., Kim, K. & Ryu, J. H. Cancer-mitochondria-targeted photodynamic therapy with supramolecular assembly of HA and a water soluble NIR cyanine dye. Chem. Sci. 8, 8351\u20138356. https:\/\/doi.org\/10.1039\/c7sc03169f (2017).","journal-title":"Chem. Sci."},{"key":"66482_CR19","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1124\/jpet.119.257725","volume":"370","author":"R Ramzan","year":"2019","unstructured":"Ramzan, R. et al. Protamine Sulfate Induces Mitochondrial Hyperpolarization and a Subsequent Increase in Reactive Oxygen Species Production. J. Pharmacol. Exp. Ther. 370, 308\u2013317. https:\/\/doi.org\/10.1124\/jpet.119.257725 (2019).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"66482_CR20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13045-024-01552-7","volume":"17","author":"NJ Short","year":"2024","unstructured":"Short, N. J., Jabbour, E., Jain, N. & Kantarjian, H. Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions. J. Hematol. Oncol. 17 , 32.https:\/\/doi.org\/10.1186\/s13045-024-01552-7 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"66482_CR21","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa1315226","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman, R. R. et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl. J. Med. 370, 997\u20131007. https:\/\/doi.org\/10.1056\/NEJMoa1315226 (2014).","journal-title":"N Engl. J. Med."},{"key":"66482_CR22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/nprot.2015.137","volume":"11","author":"N B\u00e4umer","year":"2016","unstructured":"B\u00e4umer, N. et al. Antibody-coupled siRNA as an efficient method for in vivo mRNA knockdown. Nat. Protoc. 11, 22\u201336. https:\/\/doi.org\/10.1038\/nprot.2015.137 (2016).","journal-title":"Nat. Protoc."},{"key":"66482_CR23","doi-asserted-by":"publisher","first-page":"e0200163","DOI":"10.1371\/journal.pone.0200163","volume":"13","author":"N B\u00e4umer","year":"2018","unstructured":"B\u00e4umer, N. et al. Downregulation of PIK3CA via antibody-esiRNA-complexes suppresses human xenograft tumor growth. PLoS One. 13, e0200163. https:\/\/doi.org\/10.1371\/journal.pone.0200163 (2018).","journal-title":"PLoS One"},{"issue":"6","key":"66482_CR24","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1158\/1078-0432.CCR-13-2017","volume":"15","author":"S B\u00e4umer","year":"2015","unstructured":"B\u00e4umer, S. et al. Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer. Clin. Cancer Res. Mar. 15 (6), 1383\u20131394 (2015).","journal-title":"Clin Cancer Res. Mar."},{"key":"66482_CR25","doi-asserted-by":"publisher","first-page":"e202419759","DOI":"10.1002\/anie.202419759","volume":"64","author":"A Roshanzadeh","year":"2025","unstructured":"Roshanzadeh, A. et al. Next-generation photosensitizers: Cyanine-carborane salts for superior photodynamic therapy of metastatic cancer. Angew. Chem. Int. Ed. Engl. 64, e202419759. https:\/\/doi.org\/10.1002\/anie.202419759 (2025).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"66482_CR26","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.3390\/molecules25112714","volume":"25","author":"F Gauthier","year":"2020","unstructured":"Gauthier, F., Bertrand, J. R., Vasseur, J. J., Dupouy, C. & Debart, F. Conjugation of doxorubicin to siRNA through disulfide-based self-immolative linkers. Molecules (Basel Switzerland). 25, 2714. https:\/\/doi.org\/10.3390\/molecules25112714 (2020).","journal-title":"Molecules (Basel Switzerland)"},{"key":"66482_CR27","doi-asserted-by":"publisher","first-page":"17119","DOI":"10.1021\/acsomega.2c00620","volume":"7","author":"Y Zhao","year":"2022","unstructured":"Zhao, Y. et al. Investigation of a dual siRNA\/chemotherapy delivery system for breast cancer therapy. ACS Omega. 7, 17119\u201317127. https:\/\/doi.org\/10.1021\/acsomega.2c00620 (2022).","journal-title":"ACS omega"},{"key":"66482_CR28","doi-asserted-by":"publisher","first-page":"11671","DOI":"10.1021\/acsomega.3c09098","volume":"9","author":"B \u015eenel","year":"2024","unstructured":"\u015eenel, B., Ba\u015faran, E., Aky\u0131l, E., G\u00fcven, U. M. & B\u00fcy\u00fckk\u00f6ro\u011flu, G. Co-delivery of siRNA and docetaxel to cancer cells by NLC for therapy. ACS Omega. 9, 11671\u201311685. https:\/\/doi.org\/10.1021\/acsomega.3c09098 (2024).","journal-title":"ACS omega"},{"key":"66482_CR29","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1089\/154545703322617023","volume":"13","author":"A Gr\u00fcnweller","year":"2003","unstructured":"Gr\u00fcnweller, A., Gillen, C., Erdmann, V. A. & Kurreck, J. Cellular uptake and localization of a Cy3-labeled siRNA specific for the serine\/threonine kinase Pim-1. Oligonucleotides 13, 345\u2013352. https:\/\/doi.org\/10.1089\/154545703322617023 (2003).","journal-title":"Oligonucleotides"},{"key":"66482_CR30","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1089\/nat.2012.0396","volume":"23","author":"S Shin","year":"2013","unstructured":"Shin, S. et al. Sniffing for gene-silencing efficiency of siRNAs in HeLa cells in comparison with that in HEK293T cells: correlation between knockdown efficiency and sustainability of sirnas revealed by FRET-based probing. Nucleic Acid Ther. 23, 152\u2013159. https:\/\/doi.org\/10.1089\/nat.2012.0396 (2013).","journal-title":"Nucleic Acid Ther."},{"key":"66482_CR31","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/bjh.18597","volume":"201","author":"M Harmanen","year":"2023","unstructured":"Harmanen, M. et al. Survival of patients with mantle cell lymphoma in the rituximab era: Retrospective binational analysis between 2000 and 2020. Br. J. Haematol. 201, 64\u201374. https:\/\/doi.org\/10.1111\/bjh.18597 (2023).","journal-title":"Br. J. Haematol."},{"key":"66482_CR32","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1182\/blood.2019004099","volume":"137","author":"J Crombie","year":"2021","unstructured":"Crombie, J. & LaCasce, A. The treatment of Burkitt lymphoma in adults. Blood 137, 743\u2013750. https:\/\/doi.org\/10.1182\/blood.2019004099 (2021).","journal-title":"Blood"},{"key":"66482_CR33","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber, D. A. et al. International consensus classification of myeloid neoplasms and acute leukemias: Integrating morphologic, clinical, and genomic data. Blood 140, 1200\u20131228. https:\/\/doi.org\/10.1182\/blood.2022015850 (2022).","journal-title":"Blood"},{"key":"66482_CR34","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1182\/blood.2020010144","volume":"138","author":"E Paietta","year":"2021","unstructured":"Paietta, E. et al. Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL. Blood 138, 948\u2013958. https:\/\/doi.org\/10.1182\/blood.2020010144 (2021).","journal-title":"Blood"},{"key":"66482_CR35","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12911-022-01791-z","volume":"22","author":"B Lai","year":"2022","unstructured":"Lai, B., Lai, Y., Zhang, Y., Zhou, M. & OuYang, G. Survival prediction in acute myeloid leukemia using gene expression profiling. BMC Med. Inf. Decis. Mak. 22, 57. https:\/\/doi.org\/10.1186\/s12911-022-01791-z (2022).","journal-title":"BMC Med. Inf. Decis. Mak."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-66482-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-66482-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-66482-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:07:11Z","timestamp":1787026031000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-66482-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["66482"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-66482-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"assertion":[{"value":"13 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NB, SB, WEB and GL have filed patent applications on electrostatic nanocarrier technology. GL received research grants not related to this manuscript from Abbvie, Gilead, MorphoSys, F. Hoffmann-La Roche Ltd. and Sobi. GL received honoraria from ADC Therapeutics, AbbVie, AstraZeneca, BeiGene, BMS, Genmab, Gilead, GSK, Hexal\/Sandoz, Immagene\/Flindr, Incyte, Lilly, Miltenyi, MorphoSys, MSD, Novartis, PentixaPharm, Pierre Fabre, F. Hoffmann-La Roche Ltd, and Sobi. All other authors disclose no conflict of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"25877"}}